The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.

نویسندگان

  • Ingo J Diel
  • Jean-Jacques Body
  • Alison T Stopeck
  • Saroj Vadhan-Raj
  • Andrew Spencer
  • Günther Steger
  • Roger von Moos
  • François Goldwasser
  • Amy Feng
  • Ada Braun
چکیده

BACKGROUND We compared the activity of denosumab with zoledronic acid for delaying or preventing hypercalcaemia of malignancy (HCM) in patients with advanced cancer and bone metastases or with multiple myeloma. METHODS Patient-level data were combined from two identically designed, randomised, double-blind, active-controlled, phase III trials of advanced cancer patients with breast cancer and other solid tumours (excluding breast or prostate cancer) or multiple myeloma. End-points included time to first on-study HCM, time to first and subsequent on-study HCM, proportion of patients experiencing HCM and proportion of patients experiencing recurrent HCM. RESULTS Denosumab significantly delayed the time to first on-study HCM, representing a 37% reduction in the hazard ratio (HR) compared with zoledronic acid (HR, 0.63; 95% confidence interval (CI): 0.41-0.98; P = 0.042) and reduced the risk of developing recurrent HCM (time to first and subsequent on-study HCM) by 52% (rate ratio, 0.48; 95% CI: 0.29-0.81; P = 0.006). The median time on study was 12.9 months. Fewer patients receiving denosumab compared with zoledronic acid experienced an HCM event (1.7% versus 2.7%; P = 0.028). Of the 84 patients experiencing an HCM event, 40% of those receiving zoledronic acid experienced >1 event of HCM compared with 31% of those receiving denosumab. CONCLUSION Denosumab treatment was more efficacious than treatment with zoledronic acid in delaying or preventing HCM in advanced cancer patients with breast cancer, other solid tumours or multiple myeloma.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Role of pathologic prognostic factors in breast cancer patients with isolated bone metastasis and relationship between SUVmax and prognostic factors

Introduction: 18F-FDG PET/CT provides very effective results in detecting metastases of breast cancer. In our study, we investigated the relationship between maximum standard uptake value (SUVmax) and prognostic pathologic factors in breast cancer cases with isolated bone metastasis and whether there was any difference in terms of prognostic pathologic factors betwee...

متن کامل

Denosumab in Patients with Giant Cell Tumor and Its Recurrence: A Systematic Review

Recent studies suggest that Denosumab reduces tumor size, therefore, makes the surgery easier with lowermorbidity. However, some studies have reported several complications for this drug. So, this systematic reviewwas performed to determine the effectiveness and safety of Denosumab in reducing bone destructions activity ofgiant cell tumor and skeletal-related events (SRE) in affected patients w...

متن کامل

Bone Marrow Necrosis: Frequency and clinicopathilogical Findings in Marrow Biopsyes

  Background and Objectives: Bone marrow necrosis (BMN) is a rare and ominous complication of wide variety of diseases including hematologic malignancy. This study was performed to identify frequency and the underlying associated diseases of marrow necrosis. Materials and Methods: In this descriptive study, totally 850 bone marrow trephine biopsies related to living patients at the Pathology ...

متن کامل

Bone Microenvironment and Role of Rank-Rankl-Opg in Breast Cancer Metastasis in Bone

Bone is a frequent site for distant metastasis and more prevalent in breast cancer patients. In advanced breast cancer, more than two thirds of patients will develop high rates of relapse in bone [1,2]. During the bone metastatic phase of breast cancer disease, nearly 50% of patients will be affected by skeletal related events (SRE) including pathologic fracture, bone surgery, spinal cord compr...

متن کامل

Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.

BACKGROUND Bone metastases are a common complication of prostate cancer, so treatment and prevention are essential to slow the progression of the disease and the occurrence of skeletal related events (SREs), which have devastating consequences for the quality of life of patients. SUMMARY OF EVIDENCE Bone metastases are characterized by increased bone turnover and altered balance between osteo...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • European journal of cancer

دوره 51 11  شماره 

صفحات  -

تاریخ انتشار 2015